Top

Published in:

01-10-2010 | Original paper

Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival

Authors: LaCreis R. Kidd, Guy N. Brock, Tiva T. VanCleave, Marnita L. Benford, Nicole A. Lavender, Traci L. Kruer, James L. Wittliff

Published in: Cancer Causes & Control | Issue 10/2010

Abstract

Introduction

Breast cancer (BrCA) risk stratification using clinico-pathological biomarkers helps improve disease prognosis prediction. However, disease recurrence rates remain unfavorable and individualized clinical management strategies are needed. Consequently, we evaluated the influence of 14 sequence variants detected in IL-10, TGF-β1, VEGF, and their associated receptors as effective predictors of BrCA clinical outcomes.

Methods

Tumor DNA samples collected from 441 BrCA patients were genotyped using TaqMan-PCR. Most selected targets alter cytokine serum/plasma levels or signaling pathways. Relationships between genetic profiles and recurrence as well as disease-related mortality were evaluated using cumulative incidence curves and competing risk regression models.

Results

The VEGF ⁻²⁵⁷⁸C allele was associated with a 1.3- to 1.6-fold increase in BrCA recurrence (HR_trend = 1.28; 95% CI = 0.96–1.72) and disease-related mortality (HR_trend = 1.56; 95% CI = 0.93–2.56). Although this marker was marginally significant relative to BrCA outcomes, there were substantial gains in the 5- and 8-year predictive accuracy compared to standard prognostic indicators. Among ER⁺/PR⁺ status patients, there was a significant impact of the VEGF ⁻²⁵⁷⁸CC genotype on disease recurrence and predictive accuracy.

Conclusions

Our findings suggest inheritance of the VEGF ⁻²⁵⁷⁸C allele could serve as an independent prognostic indicator of BrCA prognosis. The VEGF ⁻²⁵⁷⁸ marker may have clinical implications among a subset of ER⁺/PR⁺ patients with an aggressive phenotype. Because the VEGF ⁻²⁵⁷⁸C allele is linked to high VEGF expression, this cytokine is a potential prognostic and targeted clinical management tool.

Wu JM, Bensen-Kennedy D, Miura Y et al (2005) The effects of interleukin 10 and interferon gamma cytokine gene polymorphisms on survival after autologous bone marrow transplantation for patients with breast cancer. Biol Blood Marrow Transplant 11(6):455–464CrossRefPubMed

Stearns ME, Fudge K, Garcia F, Wang M (1997) IL-10 inhibition of human prostate PC-3 ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression. Invasion Metastasis 17(2):62–74PubMed

Stearns ME, Rhim J, Wang M (1999) Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res 5(1):189–196PubMed

Stearns ME, Wang M (1998) Antimestatic and antitumor activities of interleukin 10 in transfected human prostate PC-3 ML clones: orthotopic growth in severe combined immunodeficient mice. Clin Cancer Res 4(9):2257–2263PubMed

Williams FM, Cherkas LF, Spector TD, MacGregor AJ (2004) A common genetic factor underlies hypertension and other cardiovascular disorders. BMC Cardiovasc Disord 4(1):20CrossRefPubMed

Bello-DeOcampo D, Tindall DJ (2003) TGF-betal/Smad signaling in prostate cancer. Curr Drug Targets 4(3):197–207CrossRefPubMed

Chan LW, Moses MA, Goley E et al (2004) Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol 22(3):499–506CrossRefPubMed

Dummer W, Becker JC, Schwaaf A et al (1995) Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 5(1):67–68CrossRefPubMed

Foekens JA, Peters HA, Grebenchtchikov N et al (2001) High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61(14):5407–5414PubMed

10.

Gasparini G, Toi M, Gion M et al (1997) Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89(2):139–147CrossRefPubMed

11.

Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K (2001) Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 91(5):964–971CrossRefPubMed

12.

Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ (1995) Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 121(6):1845–1854PubMed

13.

Yang X, Letterio JJ, Lechleider RJ et al (1999) Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J 18(5):1280–1291CrossRefPubMed

14.

Shu XO, Gao YT, Cai Q et al (2004) Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai breast cancer study. Cancer Res 64(3):836–839CrossRefPubMed

15.

Chen T, Carter D, Garrigue-Antar L, Reiss M (1998) Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer. Cancer Res 58(21):4805–4810PubMed

16.

Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2(10):795–803CrossRefPubMed

17.

Guidi AJ, Schnitt SJ, Fischer L et al (1997) Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 80(10):1945–1953CrossRefPubMed

18.

Kushlinskii NE, Gershtein ES (2002) Role of vascular endothelial growth factor during breast cancer. Bull Exp Biol Med 133(6):521–528CrossRefPubMed

19.

Linderholm B, Lindh B, Tavelin B, Grankvist K, Henriksson R (2000) p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer 89(1):51–62CrossRefPubMed

20.

Linderholm BK, Lindahl T, Holmberg L et al (2001) The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res 61(5):2256–2260PubMed

21.

Jacobs EJ, Feigelson HS, Bain EB et al (2006) Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer prevention study II cohort. Breast Cancer Res 8(2):R22CrossRefPubMed

22.

Jin Q, Hemminki K, Enquist K et al (2005) Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 11(10):3647–3653CrossRefPubMed

23.

Kataoka N, Cai Q, Wen W et al (2006) Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev 15(6):1148–1152CrossRefPubMed

24.

Scheet P, Stephens M (2006) A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase. Am J Hum Genet 78(4):629–644CrossRefPubMed

25.

http://www.ncbi.nlm.nih.gov/

26.

McGuigan FE, Macdonald HM, Bassiti A et al (2007) Large-scale population-based study shows no association between common polymorphisms of the TGFB1 gene and BMD in women. J Bone Miner Res 22(2):195–202CrossRefPubMed

27.

Schneider BP, Sledge GW Jr (2007) Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Pract Oncol 4(3):181–189CrossRefPubMed

28.

Linderholm BK, Hellborg H, Johansson U et al (2009) Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 20(10):1639–1646CrossRefPubMed

29.

Faupel-Badger J, Kidd LR, Albanes D, Virtamo J, Woodson K, Tangrea JA (2008) Association of IL-10 polymorphisms with prostate risk and grade of disease. Cancer Causes Control 19(2):119–124CrossRefPubMed

30.

Krippl P, Langsenlehner U, Renner W et al (2003) A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 106(4):468–471CrossRefPubMed

31.

Nakamura M, Abe Y, Tokunaga T (2002) Pathological significance of vascular endothelial growth factor A isoform expression in human cancer. Pathol Int 52(5–6):331–339CrossRefPubMed

32.

Wang F, Wei L, Chen L (2000) The relationship between vascular endothelial growth factor, microvascular density, lymph node metastasis and prognosis of breast carcinoma. Zhonghua BingLi XueZa Zhi 29(3):172–175

33.

Ferrara N, vis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18(1):4–25CrossRefPubMed

34.

Chen Y, Wang J, Fraig MM et al (2001) Defects of DNA mismatch repair in human prostate cancer 1. Cancer Res 61(10):4112–4121PubMed

35.

Eccles S, Paon L, Sleeman J (2007) Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms. Clin Exp Metastasis 24(8):619–636CrossRefPubMed

36.

Kinoshita J, Kitamura K, Kabashima A, Saeki H, Tanaka S, Sugimachi K (2001) Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat 66(2):159–164CrossRefPubMed

37.

Lohela M, Bry M, Tammela T, Alitalo K (2009) VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 21(2):154–165CrossRefPubMed

38.

Coradini D, Biganzoli E, Pellizzaro C et al (2003) Vascular endothelial growth factor in node-positive breast cancer patients treated with adjuvant tamoxifen. Br J Cancer 89(2):268–270CrossRefPubMed

39.

Linderholm B, Bergqvist J, Hellborg H et al (2009) Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor. Med Oncol 26(4):480–490CrossRefPubMed

40.

Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B, Henriksson R (2000) Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 18(7):1423–1431PubMed

41.

Ryden L, Stendahl M, Jonsson H, Emdin S, Bengtsson NO, Landberg G (2005) Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response. Breast Cancer Res Treat 89(2):135–143CrossRefPubMed

42.

Sanchez BC, Sundqvist M, Fohlin H et al. (2010) Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF. Eur J Cancer. doi:10.1016/j.ejca.2010.03.014

43.

Garvin S, Nilsson UW, Dabrosin C (2005) Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells. Br J Cancer 93(9):1005–1010CrossRefPubMed

44.

Figg WD, Kruger EA, Price DK, Kim S, Dahut WD (2002) Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest New Drugs 20(2):183–194CrossRefPubMed

45.

Tan WW (2006) Novel agents and targets in managing patients with metastatic prostate cancer. Cancer Control 13:194–198PubMed

46.

Esteva FJ, Sahin AA, Cristofanilli M et al (2005) Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 11(9):3315–3319CrossRefPubMed

47.

van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536

48.

http://snp500cancer.nci.nih.gov/home_1.cfm

49.

Howell WM, Turner SJ, Bateman AC, Theaker JM (2001) IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2(1):25–31CrossRefPubMed

50.

Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immuno Genet 24(1):1–8

51.

Ewart-Toland A, Chan JM, Yuan J, Balmain A, Ma J (2004) A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer. Cancer Epidemiol Biomarkers Prev 13(5):759–764PubMed

52.

Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y (2000) Association of a T29–>C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 101(24):2783–2787PubMed

53.

Dunning AM, Ellis PD, McBride S et al (2003) A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 63(10):2610–2615PubMed

54.

Grainger DJ, Heathcote K, Chiano M et al (1999) Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 8(1):93–97CrossRefPubMed

55.

Lambrechts D, Storkebaum E, Morimoto M et al (2003) VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34(4):383–394CrossRefPubMed

56.

Shahbazi M, Fryer AA, Pravica V et al (2002) Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 13(1):260–264PubMed

57.

Sfar S, Hassen E, Saad H, Mosbah F, Chouchane L (2006) Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine 35(1–2):21–28CrossRefPubMed

58.

Krippl P, Langsenlehner U, Renner W et al (2003) The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk. Cancer Lett 201(2):181–184CrossRefPubMed

59.

Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E (2000) A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37(6):443–448CrossRefPubMed

60.

Park HW, Lee JE, Shin ES et al (2006) Association between genetic variations of vascular endothelial growth factor receptor 2 and atopy in the Korean population. J Allergy Clin Immunol 117(4):774–779CrossRefPubMed

Title: Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival
Authors: LaCreis R. Kidd
Guy N. Brock
Tiva T. VanCleave
Marnita L. Benford
Nicole A. Lavender
Traci L. Kruer
James L. Wittliff
Publication date: 01-10-2010
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 10/2010
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-010-9583-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2010

Consumption of filtered and boiled coffee and the risk of incident cancer: a prospective cohort study

Does socioeconomic disparity in cancer incidence vary across racial/ethnic groups?

Immunoglobulin E and cancer: a meta-analysis and a large Swedish cohort study

Polymorphisms in one-carbon metabolism pathway genes, urinary arsenic profile, and urothelial carcinoma

Male infertility and prostate cancer risk: a nested case–control study

Relationship between cancer mortality/incidence and ambient ultraviolet B irradiance in China

Keynote webinar | Spotlight on antibody–drug conjugates in cancer